Merck Reports COVID Pill Reduces Risk of Hospitalization

We’ve all seen the stories where seemingly healthy people get devastated by COVID-19. There are also numerous reports of people who eat healthily, get some sunlight, and include vitamins that barely have any symptoms.

Although including Thorne Research products is a great step for self-care, the COVID virus can create problems for anyone. That’s why Merck has worked to develop an antiviral pill while others have produced vaccinations.

The Merck COVID pill reportedly reduces the risk of hospitalization by half. 

This Pill Would Join Other Antiviral Care Products

Merck’s antiviral pill joins the infused product remdesivir and a generic steroid called dexamethasone to treat severe COVID cases. The other two products are typically given to patients once they’ve been hospitalized.

With the antiviral pill, Merck hopes to change the dialogue on how to treat or recover from COVID-19. 

The results from the Phase III study caused the company’s stock to rise nearly 10%. It produced such significant data that outside monitors recommended that the study stop early so that the treatment could proceed to market.

Merck says it is seeking emergency authorization use for the antiviral pill. 

Atea Pharmaceuticals is developing a similar product. Their shares went up by more than 20% on the news from Merck. 

With over 700,000 fatalities from COVID-19 in the United States alone, any treatment option is a welcome opportunity. Drugs similar to Merck’s have been linked to birth defects in some animal studies, but indications are that it doesn’t affect mammalian DNA – of which humans are included.